Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mean 24-hour ambulatory SBP greater than or equal to 130 mmHg~* or- Mean 24-hour ambulatory DBP greater than or equal to 80 mmHg~* Fasting LDL-C between 100 and 220 mg/dL~* Fasting triglycerides less than 400 mg/dL~* Body mass index (BMI) between 18 and 45 kg/m2~Exclusion Criteria:~* Known or suspected secondary hypertension or history of malignant hypertension~* Taking more than two anti-hypertension medications at the first visit~* History or current clinically significant cardiovascular disease~* History or current type 1 diabetes or type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 (Type: EXPERIMENTAL): ETC-1002 180 mg/day
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).